• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down Over 1%; Cognyte Software Shares Plummet

    4/9/24 2:34:43 PM ET
    $ACRV
    $CGNT
    $LASE
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $ACRV alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday.

    The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also fell, dropping, 0.39% to 5,182.36.

    Check This Out: Robinhood To Rally Around 51%? Here Are 10 Top Analyst Forecasts For Tuesday

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 0.8% on Tuesday.

    In trading on Tuesday, financial shares fell by 0.7%.

     

    Top Headline

     

    The NFIB Small Business Optimism Index declined for a third straight month to a reading of 88.5 in March, compared to market estimates of 90.2.

     

    Equities Trading UP

     

    Laser Photonics Corporation (NASDAQ:LASE) shares shot up 98% to $2.8450 after the company announced it secured an order for its LaserTower COMPACT marking and engraving system from L3Harris Technologies.

    Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) got a boost, surging 95% to $11.54. The company announced a $130 million private placement financing.

    Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares were also up, gaining 22% to $5.49. Syros received Fast Track Designation from the FDA for tamibarotene for the treatment of newly diagnosed unfit AML with RARA gene overexpression.

     

    Equities Trading DOWN

     

    Vincerx Pharma, Inc. (NASDAQ:VINC) shares dropped 75% to $1.20 after the company presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the AACR Annual Meeting 2024.

    Shares of Cognyte Software Ltd. (NASDAQ:CGNT) were down 13% to $7.33 after the company reported fourth-quarter results and issued FY25 guidance.

    Tilray Brands, Inc. (NASDAQ:TLRY) was down, falling 20% to $2.0812 after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.

    Also Check This Out: Bitcoin Falls Below $71,000 Data; Wormhole, Core Among Top Losers

     

    Commodities

     

    In commodity news, oil traded down 1.4% to $85.19 while gold traded up 0.7% at $2,367.40.

    Silver traded up 1.2% to $28.14 on Tuesday, while copper rose 0.3% to $4.2885.

     

    Euro zone

     

    European shares closed lower today. The eurozone’s STOXX 600 fell 0.61%, London’s FTSE 100 fell 0.11% while Spain’s IBEX 35 Index fell 0.88% The German DAX fell 1.32% French CAC 40 fell 0.86% while Italy’s FTSE MIB Index fell 1.08%.

    French trade deficit shrank to €5.2 billion in February 2024 versus a revised €7.2 billion gap in the prior month. Retail sales in the UK gained 3.2% from a year ago in March.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Tuesday, with Japan’s Nikkei 225 gaining 1.08%, Hong Kong’s Hang Seng Index gaining 0.57%, China’s Shanghai Composite gaining 0.05% and India’s S&P BSE Sensex falling 0.08%.

    Foreign exchange reserves in Hong Kong fell to $423.6 billion in March from $425.2 billion in the prior month. Japanese machine tool orders fell 8.5% year-over-year to JPY 135,647 million in March compared to a 8% decline in the prior month, while consumer confidence index in Japan rose to 39.5 in March versus a revised reading of 39.0 in the prior month.

     

    Economics

     

    The NFIB Small Business Optimism Index declined for a third straight month to a reading of 88.5 in March, compared to market estimates of 90.2.

    Now Read This: Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'

     

    Get the next $ACRV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRV
    $CGNT
    $LASE
    $SYRS

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Cognyte Software Ltd.
    $CGNT
    10/3/2025$14.00Buy
    Roth Capital
    Acrivon Therapeutics Inc.
    $ACRV
    5/5/2025$6.00Overweight
    Piper Sandler
    Acrivon Therapeutics Inc.
    $ACRV
    1/31/2025Overweight
    KeyBanc Capital Markets
    Acrivon Therapeutics Inc.
    $ACRV
    9/16/2024$16.00Neutral → Buy
    Ladenburg Thalmann
    Acrivon Therapeutics Inc.
    $ACRV
    4/29/2024Buy → Neutral
    Ladenburg Thalmann
    Tilray Brands Inc.
    $TLRY
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    Acrivon Therapeutics Inc.
    $ACRV
    3/1/2024$14.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Devroe Eric bought $17,218 worth of shares (10,000 units at $1.72), increasing direct ownership by 15% to 75,308 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/15/26 4:38:05 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $CGNT
    $LASE
    $SYRS
    SEC Filings

    View All

    SEC Form 424B4 filed by Laser Photonics Corporation

    424B4 - Laser Photonics Corp (0001807887) (Filer)

    2/9/26 12:19:12 PM ET
    $LASE
    Industrial Machinery/Components
    Miscellaneous

    SEC Form EFFECT filed by Laser Photonics Corporation

    EFFECT - Laser Photonics Corp (0001807887) (Filer)

    2/9/26 12:15:24 AM ET
    $LASE
    Industrial Machinery/Components
    Miscellaneous

    Laser Photonics Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Laser Photonics Corp (0001807887) (Filer)

    2/4/26 5:00:25 PM ET
    $LASE
    Industrial Machinery/Components
    Miscellaneous

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cognyte Secures $5+ Million Subscription Deal with APAC National Security Agency

    Long-standing Tier-1 customer expands deployment, unlocking new value through AI-powered analytics and creating significant growth potential over time Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in software-driven technology for investigative analytics, today announced that a national security agency in the Asia-Pacific (APAC) region has signed a five-year subscription agreement initially valued at ~$1.5 million annually. The agreement allows the customer to scale adoption of new innovations and capabilities over time, potentially growing its investment to $20+ million over the contract term. The agency, which is responsible for safeguarding national security agains

    2/12/26 8:00:00 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

    NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products across the United Kingdom. Through this agreement, CC Pharma and Smartway will jointly support the expansion of parallel import and specialist pharmaceutical supply in the UK, leveraging Smartway's established national distribution infrastructure to facilitate the delivery of pharmaceutic

    2/12/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Miller Mary covered exercise/tax liability with 659 shares, decreasing direct ownership by 2% to 33,896 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/21/26 4:02:10 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on Cognyte Software with a new price target

    Roth Capital initiated coverage of Cognyte Software with a rating of Buy and set a new price target of $14.00

    10/3/25 8:39:14 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    Piper Sandler resumed coverage on Acrivon Therapeutics with a new price target

    Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00

    5/5/25 8:30:14 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Financials

    Live finance-specific insights

    View All

    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

    Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d

    1/8/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

    WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thu

    1/6/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

    NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the second fiscal quarter which ended November 30, 2025, after the financial markets close on Thursday, January 8, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of T

    12/22/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Leadership Updates

    Live Leadership Updates

    View All

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

    Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

    4/7/25 4:05:00 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognyte Appoints Distinguished Innovator Ronny Lempel as Chief Technology Officer to Guide AI-Focused Research

    25+ years of technology expertise and leadership will continue to cultivate innovation for sustained company growth Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of Dr. Ronny Lempel as Chief Technology Officer (CTO). In this role, Lempel will apply over 25 years of proven, cross-discipline technology expertise to extend Cognyte's innovation leadership and bring unparalleled vision and value to Cognyte's customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318301357/en/Cognyte appointed Dr. Ronny Lempel as Chief Technology Officer (CTO

    3/18/25 8:00:00 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    $ACRV
    $CGNT
    $LASE
    $SYRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:24:48 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:05:24 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care